HEME / ONC - INFECTIOUS DISEASE INTEGRATED TRANSFER

YEAR 2 | PAGE 49D - CBC / SMEAR / COAGULATION / MALIGNANCY / HOST DEFENSE / ANTIMICROBIALS + 10 CASES

INTEGRATION RULE: BLOOD, CANCER AND INFECTION INTERACT THROUGH MARROW FUNCTION, IMMUNE COMPETENCE, VASCULAR / COAGULATION PHYSIOLOGY AND TREATMENT TOXICITY. IDENTIFY THE DOMINANT THREAT FIRST, THEN CONNECT THE LAB PATTERN, HOST STATE, ORGANISM OR DRUG MECHANISM. J. CROSS-SYSTEM INTEGRATION MAP

LANE	MUST RETRIEVE WITHOUT NOTES	HIGH-DISCRIMINATION TRANSFER
Sepsis -> coagulation	Severe infection can trigger endothelial injury, cytokine activation and consumptive coagulopathy.	Use platelet/PT/aPTT/fibrinogen/D-dimer plus clinical instability to separate DIC from isolated thrombocytopenia or factor deficiency.
Cancer -> infection	Marrow failure, neutropenia, mucosal injury, devices and immunosuppression change likely pathogens and urgency.	Fever in an immunocompromised host is not the same pretest probability as fever in an immunocompetent host.
Cancer -> metabolic emergency	High tumor burden and treatment can cause TLS, hypercalcemia, leukostasis or compression syndromes.	Recognize the emergency before spending time on complete histologic classification.
Antimicrobials -> blood	Some drugs cause marrow suppression, hemolysis, platelet dysfunction or interactions with anticoagulants.	Predict toxicity from drug mechanism and patient risk instead of memorizing a detached adverse-effect list.
Transfusion -> infection/inflammation	Transfusion reactions can mimic sepsis or cardiopulmonary deterioration; timing and phenotype matter.	Use reaction timing, fever/hypotension, hemolysis, pulmonary edema and volume clues to identify the pathway.

K. 10 HIGH-DISCRIMINATION INTEGRATED CASES

#	CASE	ANSWER LOGIC
1	Microcytic anemia with low ferritin and high TIBC.	Iron deficiency: first interpret iron-store/transport pattern, then investigate the source of iron loss rather than stopping at the MCV label.
2	Anemia + schistocytes + thrombocytopenia + prolonged PT/aPTT + low fibrinogen in a septic patient.	Consumptive coagulopathy/DIC pattern: infection plus global coagulation-factor/platelet consumption; distinguish from TTP/HUS where routine coagulation tests are often not globally prolonged.
3	Mucosal bleeding, normal PT, prolonged aPTT that corrects on mixing.	Factor deficiency pattern; correction with mixing argues against a strong inhibitor. Clinical bleeding phenotype and vWF/factor context narrow further.
4	Older patient, lymphocytosis, smudge-cell-type pattern, mature B-cell process.	Use age + chronic lymphoid lineage + morphology/flow context to favor CLL over acute leukemia.
5	Bone pain, anemia, renal dysfunction, hypercalcemia, monoclonal protein.	Plasma-cell disorder/myeloma pattern. The organ-damage cluster is more discriminating than the M-spike alone.
6 7	New chemotherapy, rising K/phosphate/uric acid, falling calcium, AKI. Neutropenic patient with fever and no clear source.	Tumor lysis syndrome: treatment/high burden -> rapid cell breakdown -> metabolic emergency. Treat as an urgent host-risk problem: broad empiric coverage must not wait for a perfect localization; cultures/source assessment follow without delaying care.
8	Meningitis syndrome in an older or immunocompromised host.	Start with syndrome + host to expand the empiric pathogen set; choose CSF/imaging sequence and antimicrobial coverage appropriate to risk.
9	Positive blood cultures with a prosthetic device and persistent bacteremia.	Device/biofilm context changes pathogen probability and may require source-control reasoning in addition to antibiotics.
10	Culture identifies a susceptible narrow-spectrum option after broad empiric therapy.	Definitive phase: de-escalate to the narrowest effective therapy that reaches the site and fits allergy/organ-function constraints.

L. OFFICIAL PRACTICE + READINESS STACK

RESOURCE	ROLE IN THIS REVIEW
USMLE Step 1 content specifications	Current official scope; align with school objectives and verify before testing.
NBOME COMLEX-USA Level 1	Current DO exam information and blueprint links.
CDC Transmission-Based Precautions	Official infection-control anchor for contact/droplet/airborne logic.
UWorld Step 1	Primary mixed vignette-transfer layer when used with deep review.
AMBOSS USMLE	Targeted repair + mixed questions after a defined weakness.
NBME CBSSA	External-style formative calibration interpreted with multiple signals and school policy.
TrueLearn COMLEX Level 1	COMLEX-formatted transfer option for DO learners.

L. OFFICIAL PRACTICE + READINESS STACK — M. THREE-DOMAIN MASTERY GATE

Ready to move on when you can: (1) classify anemia/hemolysis and coagulation problems from CBC, retic, smear and labs; (2) identify major hematologic malignancies from lineage, maturity, age, flow/cytogenetic and organ patterns; (3) distinguish grade, stage, treatment toxicity and oncologic emergencies; (4) move from infection syndrome + host -> pathogen set -> specimen/test -> empiric -> narrowed therapy -> resistance/prevention; and (5) maintain stable performance on new mixed questions with recurring errors shrinking. This is an educational review framework; real patient-care decisions require supervising clinicians, institutional policy and current clinical guidance. 2026/27 systems-review expanded edition - align with school objectives and verify official exam updates before testing